Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2132-2145

  Thon, Niklas ^a   Kunz, Mathias ^a   Lemke, Lena ^a   Jansen, Nathalie L ^a   Eigenbrod, Sabina ^a   Kreth, Simone ^a   Lutz, Jürgen ^a   Egensperger, Rupert ^a   Giese, Armin ^a   Herms, Jochen ^a   Weller, Michael ^b   Kretzschmar, Hans ^a   Tonn, Jörg Christian ^a   La Fougère, Christian ^a,c   Kreth, Friedrich Wilhelm ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

18F FET PET; Grading; Imaging; Low grade glioma; Prognosis

Indexed keywords

BIOLOGICAL MARKER; GADOLINIUM PENTETATE MEGLUMINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; O (FLUOROETHYL) 1 TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; TYROSINE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE DELETION; GENE MUTATION; GLIOMA; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIPLE REGRESSION; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; TUMOR BIOPSY; WORLD HEALTH ORGANIZATION; AGED; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TYROSINE; YOUNG ADULT;

EID: 84923164407     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29259     Document Type: Article

References (47)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). WHO classification of tumours of the central nervous system. 4th edn. IARC Press, Lyon 2007.
2. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: Biological features and clinical course. Lancet Neurol 2003;2: 395-403.
3. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20: 2076-84.
4. Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 2008;109: 817-24.
5. Bynevelt M, Britton J, Seymour H, et al. FLAIR imaging in the follow-up of low-grade gliomas: Time to dispense with the dual-echo? Neuroradiology 2001;43: 129-33.
6. Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59: 947-9.
7. Law M, Yang S, Wang H, et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003;24: 1989-98.
8. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg 2011;115: 948-65.
9. la Fougère C, Suchorska B, Bartenstein P, et al. Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol 2011;13: 806-19.
10. 18F]fluoroethyl)-L-Tyrosine: Uptake mechanisms and clinical applications. Nucl Med Biol 2006;33: 287-94.
11. Popperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: Correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34: 1933-42.
12. 18F]fluoroethyl)-L-Tyrosine (F-18 FET) PET for glioma grading: Assessment of individual probability of malignancy. Clin Nucl Med 2011;36: 841-7.
13. Jansen NL, Graute V, Armbruster L, et al. MRIsuspected low-grade glioma: Is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012;39: 1021-9.
14. Okubo S, Zhen HN, Kawai N, et al. Correlation of L-methyl-11C-methionine (MET) uptake with L-Type amino acid transporter 1 in human gliomas. J Neurooncol 2010;99: 217-25.
15. Kobayashi K, Ohnishi A, Promsuk J, et al. Enhanced tumor growth elicited by L-Type amino acid transporter 1 in human malignant glioma cells. Neurosurgery 2008;62: 493-503.
16. Miyagawa T, Oku T, Uehara H, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18: 500-9.
17. 18F]fluoroethyl)-L-Tyrosine in vitro and in vivo. J Nucl Med 1999;40: 1367-73.
18. Stockhammer F, Plotkin M, Amthauer H, et al. Correlation of F-18-fluoro-ethyl-Tyrosin uptake with vascular and cell density in non-contrastenhancing gliomas. J Neurooncol 2008;88: 205-10.
19. Zhang K, Langen KJ, Neuner I, et al. Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-(18)F-fluoroethyl)-L-Tyrosine uptake in cerebral gliomas. Nucl Med Commun 2014;35: 245-51.
20. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011;13: 307-16.
21. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12: 583-93.
22. Langen KJ, Bartenstein P, Boecker H, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nucl Med 2011;50: 167-73.
23. Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol 2009;68: 1219-28.
24. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. International journal of cancer. Int J Cancer 2007;121: 2458-64.
25. Hartmann C, Mueller W, Lass U, et al. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005;64: 10-4.
26. Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 2012;118: 452-60.
27. Kreth FW, Faist M, Grau S, Ostertag CB. Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: Long-Term results and prognostic factors. Cancer 2006;106: 1372-81.
28. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27: 5874-80.
29. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352: 987-96.
30. Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Adv Tech Stand Neurosurg 2010;35: 65-79.
31. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802. J Clin Oncol 2012;30: 3065-70.
32. Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-oncology 2006; 8: 253-60.
33. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47: 904-11.
34. 18F]-fluoro-ethyl-L-Tyrosine PET: A valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-oncology 2013;15: 341-51.
35. Singhal T, Narayanan TK, Jain V, et al. 11C-Lmethionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10: 1-18.
36. Rapp M, Floeth FW, Felsberg J, et al. Clinical value of O-(2-[(18)F]-fluoroethyl)-L-Tyrosine positron emission tomography in patients with low-grade glioma. Neurosurg focus 2013;34: E3.
37. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9: 906-20.
38. Jansen NL, Schwartz C, Graute V, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-oncology 2012;14: 1473-80.
39. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol 2011;99: 44-8.
40. 18F-FET PET for grading of recurrent gliomas: Is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47: 393-403.
41. 18F]fluorethyl)-L-Tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32: 422-9.
42. 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 2013;54: 229-35.
43. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
44. Ohgaki H, Burger P, Kleihues P. Definition of primary and secondary glioblastoma-response. Clin Cancer Res 2014;20: 2013.
45. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011;28: 177-83.
46. 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 2014;55: 198-203.
47. Öz G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014;270: 658-79.